OU DERMATOLOGY GRAND ROUNDS/MORPHOLOGY CONFERENCE

Course No. 22D18

Thursday, January 27, 2022

7:00 – 8:00am

**Location: 619 NE 13th Street OKC, OK 73104, 2nd floor Weigand Education Center Room 250**

**&**

**\* \* \*ZOOM PRESENTATION\* \* \***

**NOTE**: The meeting host will admit you to the meeting no earlier than 15 minutes before the scheduled start time. If you login early then please wait for the host to admit you.

Weekly Zoom Meeting

Join Zoom Meeting

<https://zoom.us/j/95768658706?pwd=MzgxaHdqSVE1M0x5cUpXbmt2dWM0UT09>

Meeting ID: 957 6865 8706

Passcode: morphology

**For CME Credit Text 10899 to 405-562-5828**

**Title: “Update on Antimalarials for the Treatment of SLE”**

Presented by:

**Aikaterini Thanou, MD**

**Assistant Professor of Medicine**

**Department of Rheumatology**

**University of Oklahoma Health Science Center**

****

**Professional Practice Gap**: (1) Practitioners may not know the role of antimalarials on SLE management, including prevention of flare, damage accrual and mortality. (2) Practitioners may not be familiar with the 2016 recommendations on screening for hydroxychloroquine (HCQ) - induced retinopathy. (3) Data emerging during the COVID pandemic have raised concerns on cardiac toxicity of HCQ, which may also be pertinent to individuals with autoimmune diseases.

**Learning Objectives:** Upon completion of this session, participants will improve their competence and performance by being able to:

1. Review the role of antimalarials on SLE disease management.
2. Review latest recommendations on antimalarial induced retinopathy screening.
3. Review latest data on cardiovascular safety of HCQ in the COVID era.

**Accreditation Statement:** The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit™.*  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

**University Equal Opportunity / Non-Discrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at link.ou.edu/reportingform.

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit [www.ou.edu/eoo](http://www.ou.edu/eoo).

**Accommodation Statement:** For accommodations, please contact Shana Levin at shana-levin@ouhsc.edu.

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

**Acknowledgement of Commercial and In-Kind Support:** **Commercial support** is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity received no commercial or in-kind support.

**Disclosure & Mitigation Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | **Nature of the Financial Relationship** | | | | |
| **Role(s)** | **First Name** | **Last Name** | **Ineligible Company** | **What Was Received** | | **For What Role?** | |
| Course Director/Speaker/Moderator | Pamela S. | Allen, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | | |
| Planning Member | Michael B. | Franzetti, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | | |
| Co-Course Director/Planning Member/Moderator | Jarad I. | Levin, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | | |
| Course Contact | Shana R. | Levin, BS | I have no financial relationships or affiliations with ineligible companies to disclose. | | | | |
| Planning Member | Nicole S. | Papac, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | | | | |
| Presenter | Aikaterini | Thanou, MD | Progentec Diagnostics, Inc. | | Consulting Fee | | Manuscript Preparer |
| **Presenter:** The conflict was resolved by Dr. Thanou agreeing that the presentation will not include discussion of any product or services from the listed commercial interest. | | | | | | | |